|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.
|
25899481 |
2015 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
|
26162609 |
2015 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer.
|
26252300 |
2015 |
|
Rectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
|
26831663 |
2016 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
|
27020587 |
2016 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation status analyses were performed in 199 tumor samples from 47 patients with rectal cancer.
|
27064574 |
2016 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
|
27184911 |
2016 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS mt status may affect the prognosis of early rectal cancer, as this is linked with distant recurrence.
|
28314302 |
2017 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.
|
28801584 |
2017 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04).
|
29048575 |
2017 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
|
29241084 |
2018 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DKI metrics with whole-tumor volume histogram analysis is associated with KRAS mutations, and thus may be useful for predicting the KRAS status of rectal cancers for guiding targeted therapy.
|
30637861 |
2019 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS status has no difference between colon cancer and rectal cancer.
|
30917791 |
2019 |
|
Rectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KLF5 was significantly associated with the presence of KRAS mutations, and KLF5 was an independent poor response predictor of CRT in rectal cancer.
|
31388510 |
2019 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterizing MRI features of rectal cancers with different KRAS status.
|
31727020 |
2019 |